story of the week
Ribociclib Plus Fulvestrant for Postmenopausal Women With HR+/HER2− Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ribociclib Plus Fulvestrant for Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in the Phase 3 Randomized MONALEESA-3 Trial: Updated Overall Survival
Ann. Oncol 2021 Jun 05;[EPub Ahead of Print], DJ Slamon, P Neven, S Chia, G Jerusalem, M De Laurentiis, S Im, K Petrakova, GV Bianchi, M Martín, A Nusch, GS Sonke, L De la Cruz-Merino, JT Beck, Y Ji, C Wang, U Deore, A Chakravartty, JP Zarate, T Taran, PA FaschingFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.